Apple stock price target raised to $240 from $235 at Morgan Stanley

Published 01/08/2025, 11:18
© Reuters

Investing.com - Morgan Stanley (NYSE:MS) raised its price target on Apple (NASDAQ:AAPL) to $240.00 from $235.00 while maintaining an Overweight rating on the stock. According to InvestingPro data, analyst targets for Apple range from $173 to $300, with 8 analysts recently revising their earnings estimates upward.

The firm cited Apple’s June quarter performance, which exceeded expectations across Product (5% beat), Services (150 basis points beat), and gross margins (50 basis points beat), even when accounting for one point of pull-forward. The company maintains a robust gross profit margin of 46.63% and has achieved revenue growth of 4.91% over the last twelve months.

Apple’s guidance for the September quarter revenue of $101 billion at the midpoint and gross margin of 46.5% midpoint (inclusive of tariffs) surpassed market expectations, according to Morgan Stanley.

The investment bank noted that Apple shared more detailed thoughts around AI, including ramping infrastructure spending, than in any prior earnings calls.

Morgan Stanley identified significant risk events that remain for Apple, specifically the imminent announcement of Section 232 tariffs and the upcoming US v. Google (NASDAQ:GOOGL) remedy ruling, which could impact the stock’s momentum.

In other recent news, Apple Inc. reported its fiscal third-quarter earnings for 2025, surpassing analyst expectations. The company achieved a revenue of $94 billion, exceeding forecasts by 5.66%. Additionally, Apple reported earnings per share (EPS) of $1.57, which was 10.56% higher than anticipated. Despite these strong results, the company’s shares experienced a minor decline in after-hours trading. These developments highlight Apple’s continued financial performance amidst market dynamics. The earnings report indicates robust operational achievements, aligning with analysts’ projections. Such results are crucial for investors evaluating Apple’s financial health and strategic direction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.